| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 1 | +1K | 0.2% | $6.69 | +$6.69K |
| Sells | 6 | -490K | 99.8% | $9.53 | -$4.66M |
| Net | -5 | -489K | -99.6% | -$4.66M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| GSK plc | 10%+ Owner | $134M | Sep 27, 2024 | ||
| Ra Capital Management, L.P. | Director, 10%+ Owner | $122M | +$6.69K | +0.01% | Nov 13, 2025 |
| Ken Takanashi | Director | $57.7M | -$42.6K | -0.07% | Aug 11, 2025 |
| Gregory L. Verdine | Director | $2.85M | -$309K | -9.76% | Aug 22, 2025 |
| Paul Bolno | President and CEO, Director | $1.22M | -$3.81M | -75.7% | Aug 22, 2025 |
| Chandra Vargeese | Chief Technology Officer, Head of Platform Discovery Sciences | $899K | Mar 4, 2025 | ||
| Michael A. Panzara | Chief Medical Officer, Head of Therapeutics Discovery and Development | $546K | Jul 25, 2022 | ||
| Mark Corrigan | Director | $453K | Aug 11, 2025 | ||
| Heidi Wagner | Director | $453K | Aug 11, 2025 | ||
| Aik Na Tan | Director | $374K | -$204K | -35.3% | Aug 15, 2025 |
| Christian O. Henry | Director | $261K | -$188K | -41.8% | Aug 11, 2025 |
| Kyle Moran | Chief Financial Officer | $221K | Feb 4, 2025 | ||
| Adrian Rawcliffe | Director | $86.2K | -$109K | -55.9% | Nov 13, 2025 |
| Chris Francis | SVP, Corporate Development, Head of Emerging Areas | $62K | Feb 4, 2025 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|